|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions显示文摘During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2(HER-2) positive breast cancer. Trastuzumab, pertuzumab, adotrastuzumab emtansine and lapatinib are currently food and drug administration(FDA)-approved for the treatment of breast cancer patients with HER-2 overexpressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated informationrelated to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. | Gonzalo Recondo Jr Enrique Dìaz Canton Màximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Clinical Oncology2014，5，3： | 7 |
| 2 | Pacemaker therapy in very elderly patients: survival and prognostic parameters of single center experience显示文摘Background Permanent pacing is the therapy of choice for treating severe and/or symptomatic bradyarrhythmias. The number of very elderly patients receiving pacemakers is increasing and little is known about survival in this specific subgroup. This study is aimed at assessing the actual survival of patients requiring pacing therapy at age > 85 years and investigating variables associated with death. Methods Between 2010 and 2017, 572 patients aged ≥ 85 years underwent pacemaker implantation for conventional bradycardia indications in Department of Cardiology, S. Chiara Hospital, Italy. Results Thirty percent of patients were ≥ 90-year-old and comorbidities were frequent. Fifty-seven percent of patients required pacing for prognostic reasons(acquired atrioventricular block), and the remaining for relief of bradycardia symptoms. A dual-chamber pacemaker was implanted in 34% of patients. The 5-year survival was 45%(standard error: 3%), and the 8-year survival was 26%(standard error: 4%). The risk of death was similar in patients who received pacemaker for symptom relief and for prognostic reasons in the overall population(HR = 1.19, 95% CI: 0.93–1.52, P = 0.156), as well as in the ≥ 90-year-old group(HR = 1.39, 95% CI: 0.92–2.11, P = 0.102). At multivariate analysis, following variables were associated with death: higher age, lower ejection fraction, dementia/dysautonomia and diagnosis of cancer. The pacing indication and the implantation of a single chamber pacemaker were not associated with worse prognosis. Conclusions This study showed a good life expectancy in patients aged ≥ 85 years who received a pacemaker. Strong risk factors for all-cause death were non-cardiac. Pacemaker therapy seems a clinically effective therapeutic option to improve survival and to control bradyarrhythmia-related symptoms in very elderly patients. | Massimiliano Marini Marta Martin Michela Saltori Silvia Quintarelli Filippo Zilio Fabrizio Guarracini Alessio Coser Sergio Valsecchi Roberto Bonmassari | 2019 | Journal of Geriatric Cardiology2019，16，12： | 3 |
| 3 | Advances and new perspectives in the treatment of metastatic colon cancer显示文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease. | Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Gastrointestinal Oncology2014，6，7： | 2 |
| 4 | Do disrupted early attachments affect the relationship between guide dogs and blind owners 显示文摘 | FaUani G Previde EP Valsecchi P | 2006 | Appl Anim Behav Sci2006，100，34： | 1 |
| 5 | Medical thoracoscopy in MALT lymphoma causing pleural effusion: A case report 显示文摘 | Arondi S Valsecchi A Marchetti G | 2015 | Tho- rac Cancer2015，6，3： | 1 |
| 6 | 显示文摘 | CAVALLI S POLESELLO S VALSECCHI S | 2005 | J Chromatogr A2005，1085，： | 1 |
| 7 | Differences in heart rate turbulence between patients with coronary artery disease and patients with ventricular arrhythmias but structurally normal hearts显示文摘 | Sestito A Valsecchi S Infusino F | 2004 | Am J Cardiol2004，93，9： | 1 |
| 8 | Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival 显示文摘 | Parazzini F Valsecchi G Bulis G | 1999 | Gynecol Oncol1999，74，1： | 1 |
| 9 | Oral ziprasidone in thetreatment of patients with bipolar disorders: a critical review显示文摘 | Sacchetti E Galluzzo A Valsecchi P | 2011 | Expert Rev Clin Pharmacol2011，4，2： | 1 |
| 10 | Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow显示文摘 | Basso G Veltroni M Valsecchi MG | | 0，，31： | 1 |
| 11 | In vitro activation of mononuclear ceUs by two probiotics: Lactobacilluz paracasei 1688, Lactobacillus salivarius I 1794, and their mixture (PSMIX) 显示文摘 | Castellazzi AM Valsecchi C Montagna L | 2007 | Immunol Invest2007，36，4： | 1 |
| 12 | Effects of low-dose heparin infusion on arterial endothelin-1 release in humans显示文摘 | Piatti PM Monti LD Valsecchi G | 1996 | Circulation1996，94，11： | 1 |
| 13 | Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol 2显示文摘 | Arico M Valsecchi MG Conter V | 2002 | Blood2002，100，2： | 1 |
| 14 | The soy isoflavone genistein reverses oxidative and inflammatory state, neu- ropathic pain, neurotrophic and vasculature deficits in diabetes mouse model显示文摘 | VALSECCHI A E FRANCHI S PANERAI A E | 2011 | Eur J Phammcol2011，650，23： | 1 |
| 15 | Intravenous neural stem cellsabolish nociceptive hypersensitivity and rigger nerve regenera- tion in experimental neuropathy 显示文摘 | Franchi S Valsecchi AE Borsani E | 2012 | Pain2012，153，： | 1 |
| 16 | What is the rele- vance of Ikaros gene deletions as a prognostic marker in pediat- ric Philadelphia-negative B-cell precursor acute lymphoblas- tic leukemia?显示文摘 | Pahni C Valsecchi MG Longinotti G | 2013 | Haernatologica2013，98，8： | 1 |
| 17 | Safety,feasibility and efficacy of transradial primary angioplasty in patients with acute myocardial infarction显示文摘 | Valsecchi O Musumeci G Vassileva A | 2003 | Ital Heart J2003，4，： | 1 |
| 18 | Role of carboplatin in the treatment of triple negative early-stage breast cancer 显示文摘 | Valsecchi ME Kimmey G Bir A | 2015 | Rev Recent Clin Trials2015，10，2： | 1 |
| 19 | Pelvic and paraorticlymph nodal status in advanced ovarian cancer and survival显示文摘 | Parazzini F Valsecchi G Bolis G | 1999 | Gynecol Oncol1999，74，1： | 1 |
| 20 | Microbial biomass, activity and organic matter accumulation in soils contaminated with heavy metals显示文摘 | Valsecchi G | 1995 | Biology and Fertility of Soil1995，20，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员